Labotec Corporate Video

Grow, Nurture, Evolve | Science & Technology | Southern Africa

This video is a passionate expression of Labotec’s 60 years in Science & Technology as an equipment supplier of laboratory equipment and solutions. Southern Africa has seen an evolution of science activity in this time. Through symbiotic partnerships with scientists, researchers and others in industry, more than half a century has been eventful and challenging. Over the years, the shaping of Labotec’s story is simply a reflection of your scientific story.

Labotec is a Scientific Equipment Supply Company | ISO 9001:2015

Labotec, a supplier of laboratory equipment to sub-Saharan Africa, was established in 1960 as one of the first laboratory supply companies in South Africa. Labotec has partnered with some of the world’s leading brands, bringing the best quality home to help empower laboratories and manufacturers to make more accurate diagnostic decisions, advance research methods and results and improve production performance in diverse fields such as food & beverage, microbiology, chemistry, physics, medical, industrial, and pharmaceutical. Labotec technical support offers after-sales service on all our products to ensure that clients receive true value from their investment to operate effectively, efficiently, and economically.

The product divisions at Labotec are the Medical and General Lab Divisions. The medical division includes product lines such as centrifuges, bioprocessing fermenters, ULT freezers, and ductless fume hoods. The General Lab division is complimented with products such as ovens, incubators, furnaces, pH meters, NIR, rotovapors, water purification systems, fat extractors, protein determination, refrigerated circulators, and more.

Download the Product Catalogue South Africa

Download the Product Catalogue Nairobi Kenya


Mission Statement

Labotec’s mission is to supply turnkey solutions and innovative products and services to the scientific community. Our products, professional advice and technical support will empower laboratories and manufacturers to make more accurate diagnostic decisions, advance research methods and results, and improve production performance by:

  • Harnessing and delivering international expertise
  • Supplying a complete offering of high quality products and services


Labotec’s vision is to be the best at understanding and satisfying the needs of laboratories and manufacturers in the African region, through evolving partnerships and mutual growth with our clients.

Board of Directors

Stan Whiting


Stan Whiting is a Director of Resolve Corporate Services (Pty) Ltd. With over 30 years’ experience in corporate advisory, he has consulted to and served as director to various corporates and SMEs, both in South Africa and abroad. Stan’s areas of expertise lie in business and strategic development, the facilitation of mergers and acquisitions, and corporate and development funding.

Stan obtained a tertiary education at the University of the Witwatersrand (WITS) and the University of South Africa (UNISA) before becoming involved with the ownership and management of a variety of companies across a broad industry spectrum. The experience garnered during this period allowed Stan to ultimately own and operate a successful business and management consultancy practice.

Ruth Tamer Field


Ruth Field is the Market Access Director for AstraZeneca Pharmaceuticals (Pty) Ltd in South Africa. She leads the strategic direction of AstraZeneca’s Access Strategy for the AstraZeneca portfolio which includes Health Economics, Pricing and Reimbursement as well as Government Affairs.

Focus Therapeutic areas; Oncology; Cardiovascular; Diabetes; Respiratory

During her extensive (over  25 years) experience in the Pharmaceutical Industry spanning several high impact positions, Ruth has been instrumental in developing and implementing innovative access solutions, achieving optimal pricing reimbursement, other access conditions as well as securing high level Government Affairs engagements.

She is a recognized as an active leader in South Africa’s bio pharmaceutical industry serving as the AstraZeneca South Africa Representative with Government officials, industry trade associations, think tanks and influential policy organizations. Ruth has worked for Novartis, Abbott, Eli Lilly and Merck. Respective Country responsibilities in various roles: Sub Saharan Africa (including South Africa); East Africa; Lusophone countries (Angola and Mozambique).

Eline Blaauboer


Eline Blaauboer has worked in the venture capital and private equity sector in both Europe and Africa for the last 22 years. She started her career at Gilde Investment Management in the Netherlands focused on tech investments in Europe.

Since 2005 she has been focused on setting up and managing various venture capital and impact funds in Africa (TBL Mirror Fund, Safaricom Spark Venture Fund I and II, Africa tech Ventures and Investment Funds for Healthcare in Africa or IFHA).

She is a co-founder and the founding chair of the East Africa Venture Capital Association. Eline furthermore has been advising various impact funds in the field of agriculture, gender balance and media in both Europe and Africa (FAFIN, IDH Farmfit Fund, Vereniging Veronica and Afrishela Fund by Graça Machel trust). Eline joined IFHA as Partner in 2021.

Felix Claus


Felix Claus is an Investment Manager at IFHA-II and represents the fund on the supervisory boards of portfolio companies Labotec and C-Care International (Alternate Director). He first joined the IFHA team in 2016 as an Investment Analyst & ESD Manager. After a successful IFHA-II-led Series A round of the technology scale-up CarePay in 2019, Felix joined CarePay full-time for 2 years in Special Projects and Corporate Finance, before coming back to IFHA at the end of 2021.

Felix holds a Master of Science in Corporate Finance from Bayes Business School and has been passionate about impact investing since discovering the field in his Bachelor Thesis titled “Methods to Sustain and Maximize Social Impact Creation in the Post-Investment Exit Phase”.

Executive Members

Ambigai Naidoo

Group CEO

Ambigai is a highly accomplished and astute Executive Management Professional, with nearly two decades of experience within the Science and Healthcare industry.  She presents with significant career success in driving bottom-line delivery and expanding business footprints across South Africa and Sub-Saharan Africa.

Ambigai has enjoyed a steady career trajectory in her longstanding tenure with a reputable clinical diagnostic and life science Company, the Scientific Group. As a seasoned life sciences sales veteran, she was promoted several times to eventually take the reins as CEO, spearheading strategies that effect aggressive market share growth and maximize business productivity, and synergy. Following an 18-month sabbatical between July 2017 – April 2019 she re-joined the industry in a marketing role at Roche Diagnostics and subsequently joined Adcock Ingram as a commercial head for Pathology. She joined the Labotec Team in December 2022 as Head of Sales and Marketing.

An intuitive leader, she largely attributes her success to her relentless pursuit towards exceptional service, her ability to identify key commercial opportunities, and her talent for building solid strategic alliances.

Dedicated to shareholder values by incorporating people and processes and with the relevant qualifications, bolstered by commercial intelligence and networking prowess acquired through many years in the field, she provides robust direction and governance in developing and implementing best practices across multiple functions.

John Harding

Group CFO

John Harding joined Labotec in 1998, and has held various positions within the business management division including General Manager of Admin and Finance. Since 2014, he has held the position of Administration and Finance Director of Labotec. Academic qualifications include an N-Dip in Cost and Management accounting and FCIS qualification with the institute of Chartered Secretaries and Administrators.